肉毒神经毒素注射治疗上肢肌张力障碍性震颤的随机临床试验
该安慰剂对照平行组随机临床试验纳入30例上肢肌张力障碍性震颤成人患者,按1:1随机接受个体化肌电引导的肉毒神经毒素(BoNT)或生理盐水注射。6周时BoNT组Fahn-Tolosa-Marin震颤评定量表总分显著低于安慰剂组(校正均差-10.9,95%CI -15.4至-6.5,P<.001),12周时差异仍显著(校正均差-5.7,95%CI -11.0至-0.5,P=.03)。组间主观手无力和握力差异无统计学意义。
要点
- 个体化肌电引导BoNT注射可显著降低上肢肌张力障碍性震颤的严重程度。
- 6周疗效最明显,12周时仍有统计学意义的改善。
- 主观手无力与握力在BoNT组与安慰剂组间无显著差异。
核心结论
- 在上肢肌张力障碍性震颤患者中,肉毒神经毒素注射在减轻震颤严重程度方面优于安慰剂。
- 按震颤现象学表现个体化选择肌肉和剂量可获得获益,且未出现不可接受的不良反应。
研究设计与样本
- 安慰剂对照、平行组随机临床试验,在一家三级大学医院运动障碍门诊开展。
- 筛查48例成人上肢肌张力障碍伴震颤患者,排除15例、拒绝3例,最终纳入30例,BoNT组与安慰剂组各15例。
- 按1:1比例用计算机生成随机序列分组,采用不透明信封隐藏分配,受试者、注射者、结局评估者和统计师均设盲。
- 招募时间为2018年11月20日至2019年12月12日,末次随访于2020年3月完成。
- 干预为肌电引导下上肢震颤肌肉肌内注射BoNT或生理盐水0.9%,注射模式和剂量按震颤现象学个体化。
主要发现
- 意向治疗组中,BoNT组6周时Fahn-Tolosa-Marin震颤评定量表总分显著低于安慰剂组(校正均差-10.9,95%CI -15.4至-6.5,P<.001)。
- 12周时BoNT组评分仍显著低于安慰剂组(校正均差-5.7,95%CI -11.0至-0.5,P=.03)。
- 患者总体变化印象(PGIC)评估中BoNT组更多报告整体改善(PGIC 1、2、3级:BoNT组4例[26.7%]、6例[40.0%]、5例[33.3%];安慰剂组5例[33.3%]、10例[66.7%]、0例;P=.047)。
- 主观手无力(BoNT组6例[40.0%],安慰剂组4例[28.6%],P=.52)与握力计评估的握力(均差-0.2 log10[kgf/m2]2/Hz-Hz,95%CI -0.9至0.4 log10[kgf/m2]2/Hz-Hz,P=.45)两组相似。
临床怎么用
- 对于上肢肌张力障碍性震颤,可考虑在肌电引导下按震颤现象学个体化选择肌肉与剂量注射肉毒神经毒素。
- 注射后6周评估震颤改善,12周时疗效仍可维持但幅度减小,可据此安排复评与后续开放标签治疗。
- 需关注主观手无力,但本试验中其发生率与握力变化同安慰剂组无显著差异。
局限性
- 样本量较小,仅30例,且86.7%为男性,外推性受限。
- 为单中心研究,随访至12周,缺乏更长疗程与重复注射周期的数据。
- 采用个体化注射模式与剂量,具体方案难以标准化推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is an unmet need for safe and efficacious treatments for upper-extremity dystonic tremor (DT). To date, only uncontrolled retrospective case series have reported the effect of botulinum neurotoxin (BoNT) injections on upper-extremity DT. OBJECTIVE: To assess the effect of BoNT injections on tremor in patients with upper-extremity DT. DESIGN, SETTING, AND PARTICIPANTS: In this placebo-controlled, parallel-group randomized clinical trial, 30 adult patients with upper-extremity DT treated at a movement disorder clinic in a tertiary care university hospital were randomized in a 1:1 ratio to BoNT or saline injection, 0.9%, using a computer-generated randomization sequence. Randomization was masked using opaque envelopes. The participant, injector, outcome assessor, and statistician were blinded to the randomization. Participants were recruited between November 20, 2018, and December 12, 2019, and the last follow-up was completed in March 2020. INTERVENTIONS: Participants received electromyographically guided intramuscular injections of BoNT or placebo into the tremulous muscles of the upper extremity. Injection patterns and doses were individualized according to tremor phenomenologic findings. MAIN OUTCOMES AND MEASURES: The primary outcome was the total score on the Fahn-Tolosa-Marin Tremor Rating Scale 6 weeks after the intervention. Outcomes were assessed at baseline, 6 weeks, and 12 weeks. All patients were offered open-label BoNT injections after 12 weeks and reassessed 6 weeks later. RESULTS: A total of 48 adult patients with a diagnosis of brachial dystonia with DT were screened. Fifteen were ineligible and 3 refused consent; therefore, 30 patients (mean [SD] age, 46.0 [18.6] years; 26 [86.7%] male) were recruited, with 15 randomized to receive BoNT and 15 to receive placebo. In the intention-to-treat group, the Fahn-Tolosa-Marin Tremor Rating Scale total score was significantly lower in the BoNT group at 6 weeks (adjusted mean difference, -10.9; 95% CI, -15.4 to -6.5; P < .001) and 12 weeks (adjusted mean difference, -5.7; 95% CI, -11.0 to -0.5; P = .03). More participants in the BoNT group reported global improvement on the Global Impression of Change (PGIC) assessment (PGIC 1, 2, and 3: BoNT: 4 [26.7%], 6 [40.0%], and 5 [33.3%]; placebo: 5 [33.3%], 10 [66.7%], and 0, respectively; P = .047). Subjective hand weakness (BoNT: 6 [40.0%]; placebo: 4 [28.6%], P = .52) and dynamometer-assessed grip strength (mean difference, -0.2 log10[kgf/m2]2/Hz-Hz; 95% CI, -0.9 to 0.4 log10[kgf/m2]2/Hz-Hz; P = .45) were similar in both groups. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, botulinum neurotoxin injections were superior to placebo in reducing tremor severity in upper-extremity DT. An individualized approach to muscle selection and dosing was beneficial without unacceptable adverse effects. TRIAL REGISTRATION: Clinical Trials Registry of India (http://ctri.nic.in) Identifier: CTRI/2018/02/011721.
引用
- Rajan R, Srivastava AK, Anandapadmanabhan R, et al. Assessment of Botulinum Neurotoxin Injection for Dystonic Hand Tremor: A Randomized Clinical Trial. JAMA Neurol. 2021. PMID: 33346814. doi:10.1001/jamaneurol.2020.4766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。